The thyroid imaging reporting and data system on US, but not the BRAFV600E mutation in fine-needle aspirates, is associated with lateral lymph node metastasis in PTC

Vivian Y. Park, Eun Kyung Kim, Hee Jung Moon, Jung Hyun Yoon, Jin Young Kwak

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The majority of patients with papillary thyroid carcinoma (PTC) have an excellent prognosis, but some show poorer outcomes and would benefit from adjunctive prognostic tools. The B-Raf proto-oncogene, serine/threonine kinase (BRAF)V600E mutation, either based on both its presence or its quantitative measurement, and ultrasound (US) features may serve as a prognostic marker. The aim of this study was to investigate (1) the association between clinical-pathologic prognostic factors and the BRAFV600E mutation found in fine-needle aspirates, based on both its presence and its corresponding cycle threshold (Ct) value, and (2) the association between prognostic factors and suspicious US features classified by the thyroid imaging reporting and data system (TIRADS) in PTC. Two-hundred fifty-eight consecutive patients with PTC > 1cmand who underwent preoperative US-guided fine-needle aspiration were included in this retrospective study. Clinical-pathologic variables were compared between patients with and without the BRAFV600E mutation. Multivariate analyses were performed to investigate (1) the association between clinical-pathologic prognostic factors and the BRAF V600Emutation found in fine-needle aspirates, based on both its presence and corresponding Ct values, and (2) the association between prognostic factors and suspicious TIRADS US features. BRAFV600E-positive patients had a higher proportion of multiple tumors (P=0.017). The number of suspicious US features classified by the TIRADS was an independent factor for predicting lateral lymph node metastasis, both in all 258 patients (odds ratio [OR]=1.902, P=0.005) and in 214 BRAFV600E-positive patients (OR=1.686, P=0.037). The BRAFV600E mutation status or BRAFV600ECt values were not associated with any of the clinical-pathologic prognostic factors. In conclusion, a higher number of suspicious US features classified by the TIRADS, but not the BRAFV600E mutation, are associated with lateral lymph node metastasis in patients with PTC, and can aid in the preoperative identification of patients at increased risk of lateral lymph node metastasis.

Original languageEnglish
Article numbere4292
JournalMedicine (United States)
Volume95
Issue number29
DOIs
Publication statusPublished - 2016 Jul 26

Fingerprint

Information Systems
Needles
Thyroid Gland
Lymph Nodes
Neoplasm Metastasis
Mutation
Odds Ratio
Proto-Oncogenes
Papillary Thyroid cancer
Protein-Serine-Threonine Kinases
Fine Needle Biopsy
Multivariate Analysis
Retrospective Studies
Neoplasms

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{e8d67cb93b65416aa4ee973c29ccaa63,
title = "The thyroid imaging reporting and data system on US, but not the BRAFV600E mutation in fine-needle aspirates, is associated with lateral lymph node metastasis in PTC",
abstract = "The majority of patients with papillary thyroid carcinoma (PTC) have an excellent prognosis, but some show poorer outcomes and would benefit from adjunctive prognostic tools. The B-Raf proto-oncogene, serine/threonine kinase (BRAF)V600E mutation, either based on both its presence or its quantitative measurement, and ultrasound (US) features may serve as a prognostic marker. The aim of this study was to investigate (1) the association between clinical-pathologic prognostic factors and the BRAFV600E mutation found in fine-needle aspirates, based on both its presence and its corresponding cycle threshold (Ct) value, and (2) the association between prognostic factors and suspicious US features classified by the thyroid imaging reporting and data system (TIRADS) in PTC. Two-hundred fifty-eight consecutive patients with PTC > 1cmand who underwent preoperative US-guided fine-needle aspiration were included in this retrospective study. Clinical-pathologic variables were compared between patients with and without the BRAFV600E mutation. Multivariate analyses were performed to investigate (1) the association between clinical-pathologic prognostic factors and the BRAF V600Emutation found in fine-needle aspirates, based on both its presence and corresponding Ct values, and (2) the association between prognostic factors and suspicious TIRADS US features. BRAFV600E-positive patients had a higher proportion of multiple tumors (P=0.017). The number of suspicious US features classified by the TIRADS was an independent factor for predicting lateral lymph node metastasis, both in all 258 patients (odds ratio [OR]=1.902, P=0.005) and in 214 BRAFV600E-positive patients (OR=1.686, P=0.037). The BRAFV600E mutation status or BRAFV600ECt values were not associated with any of the clinical-pathologic prognostic factors. In conclusion, a higher number of suspicious US features classified by the TIRADS, but not the BRAFV600E mutation, are associated with lateral lymph node metastasis in patients with PTC, and can aid in the preoperative identification of patients at increased risk of lateral lymph node metastasis.",
author = "Park, {Vivian Y.} and Kim, {Eun Kyung} and Moon, {Hee Jung} and Yoon, {Jung Hyun} and Kwak, {Jin Young}",
year = "2016",
month = "7",
day = "26",
doi = "10.1097/MD.0000000000004292",
language = "English",
volume = "95",
journal = "Medicine (United States)",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "29",

}

TY - JOUR

T1 - The thyroid imaging reporting and data system on US, but not the BRAFV600E mutation in fine-needle aspirates, is associated with lateral lymph node metastasis in PTC

AU - Park, Vivian Y.

AU - Kim, Eun Kyung

AU - Moon, Hee Jung

AU - Yoon, Jung Hyun

AU - Kwak, Jin Young

PY - 2016/7/26

Y1 - 2016/7/26

N2 - The majority of patients with papillary thyroid carcinoma (PTC) have an excellent prognosis, but some show poorer outcomes and would benefit from adjunctive prognostic tools. The B-Raf proto-oncogene, serine/threonine kinase (BRAF)V600E mutation, either based on both its presence or its quantitative measurement, and ultrasound (US) features may serve as a prognostic marker. The aim of this study was to investigate (1) the association between clinical-pathologic prognostic factors and the BRAFV600E mutation found in fine-needle aspirates, based on both its presence and its corresponding cycle threshold (Ct) value, and (2) the association between prognostic factors and suspicious US features classified by the thyroid imaging reporting and data system (TIRADS) in PTC. Two-hundred fifty-eight consecutive patients with PTC > 1cmand who underwent preoperative US-guided fine-needle aspiration were included in this retrospective study. Clinical-pathologic variables were compared between patients with and without the BRAFV600E mutation. Multivariate analyses were performed to investigate (1) the association between clinical-pathologic prognostic factors and the BRAF V600Emutation found in fine-needle aspirates, based on both its presence and corresponding Ct values, and (2) the association between prognostic factors and suspicious TIRADS US features. BRAFV600E-positive patients had a higher proportion of multiple tumors (P=0.017). The number of suspicious US features classified by the TIRADS was an independent factor for predicting lateral lymph node metastasis, both in all 258 patients (odds ratio [OR]=1.902, P=0.005) and in 214 BRAFV600E-positive patients (OR=1.686, P=0.037). The BRAFV600E mutation status or BRAFV600ECt values were not associated with any of the clinical-pathologic prognostic factors. In conclusion, a higher number of suspicious US features classified by the TIRADS, but not the BRAFV600E mutation, are associated with lateral lymph node metastasis in patients with PTC, and can aid in the preoperative identification of patients at increased risk of lateral lymph node metastasis.

AB - The majority of patients with papillary thyroid carcinoma (PTC) have an excellent prognosis, but some show poorer outcomes and would benefit from adjunctive prognostic tools. The B-Raf proto-oncogene, serine/threonine kinase (BRAF)V600E mutation, either based on both its presence or its quantitative measurement, and ultrasound (US) features may serve as a prognostic marker. The aim of this study was to investigate (1) the association between clinical-pathologic prognostic factors and the BRAFV600E mutation found in fine-needle aspirates, based on both its presence and its corresponding cycle threshold (Ct) value, and (2) the association between prognostic factors and suspicious US features classified by the thyroid imaging reporting and data system (TIRADS) in PTC. Two-hundred fifty-eight consecutive patients with PTC > 1cmand who underwent preoperative US-guided fine-needle aspiration were included in this retrospective study. Clinical-pathologic variables were compared between patients with and without the BRAFV600E mutation. Multivariate analyses were performed to investigate (1) the association between clinical-pathologic prognostic factors and the BRAF V600Emutation found in fine-needle aspirates, based on both its presence and corresponding Ct values, and (2) the association between prognostic factors and suspicious TIRADS US features. BRAFV600E-positive patients had a higher proportion of multiple tumors (P=0.017). The number of suspicious US features classified by the TIRADS was an independent factor for predicting lateral lymph node metastasis, both in all 258 patients (odds ratio [OR]=1.902, P=0.005) and in 214 BRAFV600E-positive patients (OR=1.686, P=0.037). The BRAFV600E mutation status or BRAFV600ECt values were not associated with any of the clinical-pathologic prognostic factors. In conclusion, a higher number of suspicious US features classified by the TIRADS, but not the BRAFV600E mutation, are associated with lateral lymph node metastasis in patients with PTC, and can aid in the preoperative identification of patients at increased risk of lateral lymph node metastasis.

UR - http://www.scopus.com/inward/record.url?scp=84980039398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84980039398&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000004292

DO - 10.1097/MD.0000000000004292

M3 - Article

C2 - 27442672

AN - SCOPUS:84980039398

VL - 95

JO - Medicine (United States)

JF - Medicine (United States)

SN - 0025-7974

IS - 29

M1 - e4292

ER -